Zynaxis deal

ZNXS and Secretech Inc. reached an agreement in principle to merge the Birmingham, Ala., company with ZNXS for 3 million shares of ZNXS common stock. The merger is contingent on successful completion of a $3 million private placement. ZNXS, which has 5.2 million shares outstanding prior to the merger, closed at $1.938 on Friday.

Secretech develops orally delivered vaccines that stimulate both systemic and mucosal immunity. Its product portfolio includes an anti-allergy vaccine in Phase II trials, an influenza vaccine that will enter the clinic this year, and preclinical stage vaccines for pediatric respiratory diseases and for rotavirus. ...